Patents by Inventor Naomi Shimazaki

Naomi Shimazaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120263716
    Abstract: The method of treating a person having a cancer selected from carcinoma, sarcoma or hematopoietic cancer by administering (a) an effective amount of at least one anti-cancer drug selected from the group consisting of an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor and a Raf kinase inhibitor and (b) an effective amount of 5-(4-(6-(4-amino-3,5-dimethyl-phenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy)-benzyl)-thiazolidine-2,4-dione.dihydrochloride provided that said carcinoma is not lung cancer when an EGFR inhibitor is erlotinib. The invention also provides a pharmaceutical composition that may be used in practicing said method.
    Type: Application
    Filed: June 19, 2012
    Publication date: October 18, 2012
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kosaku FUJIWARA, Naomi Shimazaki
  • Publication number: 20120258991
    Abstract: A method of treating a cancer selected from the group consisting of breast cancer, pancreatic cancer, kidney cancer, prostate cancer, medulloblastoma, rhabdomyosarcoma, Ewing sarcoma, liposarcoma, multiple myeloma or leukemia. An effective amount of 5-(4-(6-(4-amino-3,5-dimethyl-phenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy)-benzyl)-thiazolidine-2,4-dione.dihydrochloride is administered to a patient having said cancer.
    Type: Application
    Filed: June 18, 2012
    Publication date: October 11, 2012
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kosaku FUJIWARA, Naomi SHIMAZAKI
  • Patent number: 8263631
    Abstract: Method of treating persons having carcinoma, sarcoma or hematopoietic cancer by administering (i) a compound of the formula (I) and (ii) an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor and pharmaceutical compositions for use in said method. A method for treating gastric cancer, colon cancer, lung cancer, breast cancer, pancreas cancer, kidney cancer, prostate cancer, medulloblastoma, rhabdomyosarcoma, Ewing sarcoma, liposarcoma, multiple myeloma and leukemia by administering a compound of the formula (I).
    Type: Grant
    Filed: July 30, 2008
    Date of Patent: September 11, 2012
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Kosaku Fujiwara, Naomi Shimazaki
  • Publication number: 20090028868
    Abstract: Method of treating persons having carcinoma, sarcoma or hematopoietic cancer by administering (i) a compound of the formula (I) and (ii) an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor and pharmaceutical compositions for use in said method. A method for treating gastric cancer, colon cancer, lung cancer, breast cancer, pancreas cancer, kidney cancer, prostate cancer, medulloblastoma, rhabdomyosarcoma, Ewing sarcoma, liposarcoma, multiple myeloma and leukemia by administering a compound of the formula (I).
    Type: Application
    Filed: July 30, 2008
    Publication date: January 29, 2009
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kosaku Fujiwara, Naomi Shimazaki
  • Patent number: 5409912
    Abstract: A new compound, which we have named Leustroducsin H, has formula (I): ##STR1## and pharmaceutically acceptable salts thereof. This compound may be prepared by hydrolysis of naturally occurring Leustroducsins and the compound may be used for the treatment or prophylaxis of thrombocytopenia.
    Type: Grant
    Filed: April 8, 1994
    Date of Patent: April 25, 1995
    Assignee: Sankyo Company, Limited
    Inventors: Yukio Sugimura, Tomoyuki Shibata, Kazuhiko Tamaki, Shinwa Kurihara, Takafumi Kohama, Akio Shiraishi, Tomowo Kobayashi, Kazuhiko Sasagawa, Naomi Shimazaki